With less than a month until this year’s CNS Summit Digital Innovation Index launch, let’s look back at who missed last year’s leaderboard cut.
--
15) Johnson & Johnson – Johnson & Johnson finished with an overall rank of 15th in last year’s Index, with most of their notable contributions falling under the commercial subcategory. This was highlighted by a collaboration with Apple, where the two companies came together to analyze the impacts of heart-based health apps on the Apple Watch. This comes with the goal of improving early detection of irregular heart patterns and reducing the chances of sudden strokes or other cardiovascular conditions.
14) Novo Nordisk AS – Despite a 14th place finish, Novo Nordisk made one of the more important contributions to the new wave of digital therapeutics in 2023. With their announcement of a $200 million quantum computer dedicated towards life sciences, Novo Nordisk set themselves up to be a major player in digital advancement in future Indices.
13) Takeda – Takeda excelled in the research subcategory once again in 2023’s Index, finishing in 5th place thanks to a great combination of volume and quality in the category. While Takeda placed several investments in AI, none were bigger than their $4 billion acquisition of an experimental psoriasis drug from Nimbus Therapeutics. The drug, built upon an AI model that chose certain molecules out of thousands, was one of many created or purchased by Takeda in last year’s data collection for the Index.
12) H. Lundbeck – Lundbeck finished in a respectable 12th place in last year’s Index, highlighted by some impressive uses of AI. The first of which was their funding of CerebNet, which aims to use deep learning to create a fully automated method of the lobular segmentation of the cerebellum. The second project was a study Lundbeck funded with the goal of using AI to improve the prediction of blood biomarkers.
11) Amgen – Despite a second-place finish under the clinical subcategory, Amgen just narrowly missed last year’s leaderboard with an 11th place finish. Their strong performance in clinical trials was backed by their launch of a new app “MyHeartMate” which was found to help reduce coronary heart disease in patients through games.
The competition for leadership in digital healthcare is fierce, and the next few years promise even more exciting developments. Stay informed as we reveal the top players in the 2024 CNS Summit Digital Innovation Index.
